Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Haleon PLC ( (GB:HLN) ) just unveiled an update.
Haleon plc has confirmed that as of 31 January 2026 it has 8,952,353,648 issued ordinary shares of £0.01 each, of which 45,557,120 are held in treasury, leaving 8,906,796,528 ordinary shares in issue with voting rights. The company stated that this voting share count should be used by shareholders and other market participants as the reference denominator for assessing disclosure obligations under the UK Financial Conduct Authority’s Disclosure Guidance and Transparency Rules, providing clarity for investors on Haleon’s capital and voting structure.
The most recent analyst rating on (GB:HLN) stock is a Buy with a £4.55 price target. To see the full list of analyst forecasts on Haleon PLC stock, see the GB:HLN Stock Forecast page.
Spark’s Take on GB:HLN Stock
According to Spark, TipRanks’ AI Analyst, GB:HLN is a Outperform.
Haleon PLC’s overall stock score reflects strong financial performance and positive corporate events, which are the most significant factors. Technical analysis and valuation present a more mixed outlook, with some short-term challenges. The earnings call highlights regional strengths but also points to challenges in North America. Overall, the company is well-positioned for future growth, but careful management of liabilities and strategic initiatives will be crucial.
To see Spark’s full report on GB:HLN stock, click here.
More about Haleon PLC
Haleon plc (LSE/NYSE: HLN) is a global leader in consumer health, focusing on over-the-counter products across six major categories: Oral Health, Vitamins, Minerals and Supplements, Pain Relief, Respiratory Health, Digestive Health, and Therapeutic Skin Health and Other. Its portfolio includes well-known brands such as Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu and Voltaren, underpinned by science-led innovation and a focus on everyday health needs worldwide.
Average Trading Volume: 16,405,306
Technical Sentiment Signal: Strong Buy
Current Market Cap: £33.74B
For an in-depth examination of HLN stock, go to TipRanks’ Overview page.